FRANKFURT, Jan 11 (Reuters) - German COVID-19 vaccine maker BioNTech(22UAy.DE)said it developed a method to quickly determine whether a new virus variant is a cause for concern, collaborating with British artificial intelligence startup InstaDeep Ltd.
In a joint statement on Tuesday, BioNTech and its partner said the new computational method can analyse genetic sequencing data of new coronavirus mutations found in infected people and assesses the risk they pose within days and sometimes within just minutes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments